Automated radiation could make stem cell transplants safer for blood cancer patients
NCT ID NCT07634536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new automated radiation method that precisely targets bone marrow and lymph nodes before a stem cell transplant. The goal is to kill cancer cells while reducing damage to healthy tissues. Participants have high-risk myeloid cancers like acute myeloid leukemia or myelodysplastic syndromes. The study will check if this approach is safe and helps patients recover without severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Automated total marrow and lymphoid irradiation (TMLI) with fludarabine and cyclophosphamide
What this could lead to
If successful, this automated radiation approach could make stem cell transplants safer and more effective for people with high-risk blood cancers.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. Radiation and chemotherapy still carry risks of serious side effects, including infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact